
WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.

WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.
What they do: AI-driven platform (ALFRED AI) for design and optimization of genomic medicines (AAV, lentiviral, non-viral vectors, payloads, bioproduction)
Founded: 2019
Headquarters / presence: Paris, Boston, Montréal
Funding: $10M seed (Sep 12, 2022); pre-seed tied to Y Combinator (Mar 2022)
Investors / partners: Debiopharm Group, Omnes Capital, Y Combinator
| Company |
|---|
Accelerating and de-risking genomic medicine R&D (gene and cell therapy development).
2019
Biotechnology
Pre-seed round associated with Y Combinator
10000000
Seed round announced Sep 12, 2022
“Debiopharm Group and Omnes Capital are lead investors; Y Combinator participated in earlier round”
Execute and scale the global BD & Licensing strategy to support WhiteLab Genomics’ growth objectives
Drive targeted business development initiatives to accelerate client acquisition and revenue growth
Identify, structure, and negotiate strategic partnerships, licensing deals, and collaborations with biopharma, biotech, and research institutions
Design and recommend creative deal structures and business terms to maximize value and secure successful closures
Own forecasting and reporting of BD activities (pipeline health, revenue projections, strategic KPIs), with regular updates to the Executive Team and Board of Directors
Build and nurture trusted relationships with C-level executives, investors, and scientific leaders
Partner cross-functionally with R&D, Legal, Finance, and Product teams to ensure seamless deal execution and integration
Contribute to IP protection and value-creation strategy in collaboration with internal experts
Monitor and analyze the competitive landscape, market trends, and emerging opportunities in genomic medicine to inform strategic positioning
Represent WhiteLab Genomics at industry conferences, partner meetings, and high-level negotiations to strengthen visibility and credibility### We’re Eager to Meet You If You Have…
~10 years of experience in senior Business Development, Partnerships, or Licensing roles
A Master’s degree in Business or Science (or equivalent experience); a PhD in a relevant field (e.g. Biology, Cell Therapy, Gene Therapy) is a strong plus
Proven deal-closing experience in Pharma & Biotech environments, with a strong track record of revenue generation
Demonstrated experience leading large, complex collaborations or consortia, including sophisticated IP and partnership negotiations with industrial and academic stakeholders
Deep expertise in Cell & Gene Therapies, particularly delivery system technologies (viral and non-viral vectors)
Solid understanding of AI-enabled approaches accelerating early-stage R&D, especially in genomic medicine
Consistent ability to meet and exceed ambitious sales targets
Strong strategic thinking, analytical judgment, and problem-solving skills
A well-established network within large pharmaceutical R&D organizations in the US and/or EU, ideally within Cell & Gene Therapy
A creative, adaptable mindset when addressing complex and high-stakes customer challenges- First a video call with our People & Culture team
Deeper dive – chat with the BD Team
PI assessment
Meet us in person on team meetings
Final checks – references
Let’s make it official – offer